Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Interferon Lambda Therapy for COVID-19
NCT04388709 · Icahn School of Medicine at Mount Sinai · PHASE2 · withdrawn · last registry update 2021-02-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to the number of competing trials at their site, the study team has closed enrollment and withdrawn this trial.” | – | Registry record, Icahn School of Medicine at Mount Sinai |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL10RB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-12-01Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Peg-interferon lambda + Lonafarnib (NCT03600714)
- 2021-10-07Phase 3 first posted: Eiger BioPharmaceuticals, Peginterferon Lambda-1a (NCT05070364)
- 2021-07-22Results posted on the registry: EVIVE Biotechnology, Recombinant Human Interleukin-22 IgG2-Fc (F-652) + Systemic Corticosteroids (NCT02406651)
- 2021-07-19Phase 3 first posted: University Health Network, Toronto, Peginterferon Lambda-1A (NCT04967430)
- 2021-04-22Results posted on the registry: Stanford University, Peginterferon Lambda-1a (NCT04331899)
- 2021-01-20Results posted on the registry: Eli Lilly and Company, Pegilodecakin + Pembrolizumab (NCT03382899)
- 2021-01-20Also stopped (terminated): Eli Lilly and Company, Pegilodecakin + Pembrolizumab (NCT03382899)
- 2020-10-19Results posted on the registry: Eli Lilly and Company, Pegilodecakin + FOLFOX (NCT02923921)
- 2020-09-11Results posted on the registry: Eli Lilly and Company, Pegilodecakin + Nivolumab (NCT03382912)
- 2020-09-11Also stopped (terminated): Eli Lilly and Company, Pegilodecakin + Nivolumab (NCT03382912)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision